Dupilumab (Dupixent), a fully human monoclonal antibody that targets the interleukin (IL)-4 and IL-13 pathways, is currently ...

AZ and Daiichi Sankyo have said that NICE's decision on Enhertu exposes how new methods and processes the agency uses to ...

Tagrisso has been recommended for approval in the European Union for the treatment of adult patients with locally advanced, ...

The phase 3 MK-3475A-D77 trial tested subcutaneous and intravenous Keytruda given every six weeks in combination with ...

A little more than a month after AstraZeneca jumped into the fray with the purchase of a rival heart drug candidate, Eli ...

AstraZeneca AZN announced that the EMA’s Committee for Medicinal Products for Human Use (“CHMP”) recommended approving its ...

Treatment with metformin was associated with a reduction in asthma attacks among patients with asthma and type 2 diabetes, with additional reductions observed with the use of GLP-1 receptor agonists, ...

Nice said it was ‘extremely disappointed’ it will be unable to recommend trastuzumab deruxtecan, sold under the brand name ...

Experts view BridgeBio’s acoramidis—which has an FDA action date of Nov. 29—as either similar to or incrementally better than ...

Lilly’s muvalaplin is the first oral drug to show positive Phase II findings for Lp(a) reduction, eliciting up to an 86% drop ...

Citizen Health aims to connect patients with others in the rare disease community — and leave them in control of their own ...

NPPA revises ceiling price of six formulations based on DoP's review order: Gireesh Babu, New Delhi Wednesday, November 20, 2024, 08:00 Hrs [IST] The National Pharmaceutical Prici ...